Evotec wins $74m contract from US DOD for monoclonal antibody development
Under the contract, Evotec Biologics will develop drug product prototype(s) from discovery through the execution of Phase 1…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
06 Jul 23
Under the contract, Evotec Biologics will develop drug product prototype(s) from discovery through the execution of Phase 1…
06 Jul 23
Brii Biosciences has acquired worldwide exclusive license to VBI-2601 and an exclusive license for PreHevbri in the Asia…
05 Jul 23
The EC authorisation is supported by positive data from the Phase ½ FOENIX-CCA2 clinical trial, in which Lytgobi…
04 Jul 23
The first Phase 3 results for AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody drug conjugate showed a statistically significant…
04 Jul 23
The filing follows the recommendation from regulators and global public health bodies to develop monovalent XBB.1.5 COVID-19 vaccines
03 Jul 23
Hyrimoz HCF is approved in the US to treat indications including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis,…
03 Jul 23
The newly secured funding will be utilised to expand operations and further advance the development of its groundbreaking…
03 Jul 23
Cyltezo is the only adalimumab biosimilar with Phase III comparative clinical studies in rheumatoid arthritis, plaque psoriasis and…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
30 Jun 23
Under the NEURii collaboration, partners will pool their expertise in therapeutics, technology development and commercialisation, health data management…
30 Jun 23
Lilly will purchase all the outstanding shares of Sigilon at a price of $14.92 per share, which amounts…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates